Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer
Status:
Recruiting
Trial end date:
2025-06-07
Target enrollment:
Participant gender:
Summary
This single arm pilot study evaluates the use of neoadjuvant endocrine therapy in women with
early stage ER+ breast cancer who are 65 years or older and are scheduled to have breast
conservation surgery (BCS). The purpose of this study is to see if tolerance of neoadjuvant
endocrine therapy helps inform decisions on whether or not to omit radiation. Participants
will be treated with the novel approach of 3 months of neoadjuvant endocrine therapy, so that
the participants and providers will have some indication of tolerance prior to making a
decision about radiation omission. Tolerance of the endocrine therapy will be assessed by
patient reported outcome (PRO) measures during neoadjuvant and adjuvant endocrine therapy
treatment periods. Breast cancer participants and their surgical oncologists will be asked
their preference regarding radiation therapy before starting endocrine therapy and again
pre-operatively. They will make a determination regarding radiation therapy as per standard
care. The hypothesis is that knowledge of tolerance of endocrine therapy will influence the
decision by the patient and the surgical oncologist whether or not to elect radiation
omission.